Bifogade filer
Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace mRNA study
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of LaminarPace enabling dry powder forms of ReCode’s proprietary therapeutic modalities.
Ziccum AB signed an Evaluation agreement with ReCode on June 19th, 2024. The study will focus on evaluating Ziccum’s formulation and drying technology LaminarPace to enable dry powder forms of ReCode material: therapeutic messenger-RNA in specific liquid lipid nanoparticle formulation, mRNA/LNP, on ReCode’s proprietary SORT platform.
The LaminarPace performance will be evaluated by analytical assessment of the resulting mRNA/LNP dry product, with technical parameters as well as mRNA activity in cell transfection.
CEO Ann Gidner: “We are delighted to take our dialogue with ReCode forward to a formal collaboration. The potential of enabling new and optimal applications of the targeting mRNA technology of ReCode, and their position as a leader in the intensely growing mRNA field, is indeed enticing. We are most happy to add such a strong partner and look forward to getting this work started.”